We applaud the ADA for taking this action, and agree with its assertion that Byetta and other drugs in this class need further review.
New York, New York (PRWEB) June 19, 2013
As Byetta lawsuit claims continue to mount in courts throughout the U.S., Bernstein Liebhard LLP notes that the American Diabetes Association (ADA) has called for an independent review of Byetta and similar diabetes drugs known as incretin mimetics. According to a statement issued by the group on June 10th, such a review is needed to provide clarity to patients and health care providers in light of the recent controversy concerning a possible link between Byetta and other incretin mimetics and pancreatitis and pancreatic cancer. The Association is requesting that the manufacturers of Byetta and similar medications make patient-level data available on all subjects involved in regulatory trials for an independent analysis.*
“We applaud the ADA for taking this action, and agree with its assertion that Byetta and other drugs in this class need further review,” says Bernstein Liebhard LLP, a nationwide law firm representing victims of defective drugs and medical devices. The Firm is currently offering free Byetta cancer lawsuit evaluations to patients who took this drug and were diagnosed with pancreatic cancer or thyroid cancer. Bernstein Liebhard LLP is also investigating claims related to Byetta pancreatitis.
Byetta Cancer Lawsuits
Byetta works by mimicking incretin hormones, which would normally be produced by the stomach after a meal to stimulate the release of insulin. In February 2011, research published in Gastroenterology suggested a risk of Byetta pancreatic cancer, reporting that the drug appeared to increase the likelihood for the diseases by nearly 3-fold. The same study also reported 30 cases of Byetta thyroid cancer in patients taking the drug, and a six-fold increase risk for pancreatitis among Byetta users.**
Since its 2005 approval, the U.S. Food & Drug Administration (FDA) has released a number of Byetta warnings regarding its effects on the pancreas. In 2008, for example, the agency revealed that Byetta had been associated with a high number of adverse event reports involving pancreatitis.*** Concerns about Byetta pancreatic cancer were heightened after March 14, 2013, when the FDA announced it was investigating findings from an unpublished study that suggested Byetta and other incretin mimetics could be associated with pre-cancerous cellular changes in the pancreas called pancreatic duct metaplasia.****
Court documents indicate that a number of Byetta lawsuits have been filed in courts around the country on behalf of patients who developed pancreatitis, pancreatic cancer, or thyroid cancer, allegedly due to their use of the drug. The U.S. Judicial Panel on Multidistrict Litigation (JPML) is scheduled to hear Oral Arguments on July 25th regarding the proposed establishment of a multidistrict litigation for all federal personal injury lawsuits involving Byetta and other incretin mimetics. (In Re: Incretins Products Liability, Sales and Marketing Litigation, MDL 2452, JPML)
Patients treated with Byetta who developed pancreatitis, pancreatic cancer or thyroid cancer may be entitled to compensation for medical bills and other damages. Additional information about filing a Byetta lawsuit is available at Bernstein Liebhard LLP’s website. To learn more, please call 800-511-5092.
*diabetes.org/for-media/2013/american-diabetes-association-incretin-therapy.html, ADA, June 10, 2013
** gastrojournal.org/article/S0016-5085%2811%2900172-7/abstract, Gastroenterology, February 21, 2011
***fda.gov/Drugs/DrugSafety/PostmarketDrugSafetyInformationforPatientsandProviders/ucm124713.htm; FDA, August 18, 2008
**** fda.gov/Drugs/DrugSafety/ucm343187.htm, FDA, March 14, 2013
About Bernstein Liebhard LLP
Bernstein Liebhard LLP is a New York-based law firm exclusively representing injured persons in complex individual and class action lawsuits nationwide since 1993, including those who have been harmed by dangerous drugs, defective medical devices and consumer products. The firm has been named by The National Law Journal to the “Plaintiffs’ Hot List,” recognizing the top plaintiffs’ firms in the country, for the past 10 consecutive years.
Bernstein Liebhard LLP
10 East 40th Street
New York, New York 10016
ATTORNEY ADVERTISING. © 2013 Bernstein Liebhard LLP. The law firm responsible for this advertisement is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. Prior results do not guarantee or predict a similar outcome with respect to any future matter.
Felecia L. Stern, Esq.
Bernstein Liebhard LLP
info (at) consumerinjurylawyers (dot) com